467 results on '"Besse, B."'
Search Results
2. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
3. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
4. Les tumeurs thymiques: Thymic tumors
5. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
6. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe
7. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
8. Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
9. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
10. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
11. Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting
12. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
13. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
14. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
15. Investigation of radiomics based intra-patient inter-tumor heterogeneity and the impact of tumor subsampling strategies
16. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
17. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
18. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
19. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
20. Small cell lung cancer: a slightly less orphan disease after immunotherapy
21. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
22. Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors
23. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease
24. Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
25. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
26. Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
27. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts
28. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
29. Vers une dé-escalade des traitements par immunothérapie des CBNPC avancés : pourquoi, comment ?: De-escalation strategy with immune check-point blockers in advanced non-small cell lung cancer
30. Place de l’immunothérapie dans le cancer bronchique non à petites cellules localement avancé
31. Les tumeurs thymiques
32. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer
33. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
34. Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients
35. Les tumeurs thymiques
36. Prise en charge des formes oligométastatiques : l’avis de l’oncologue thoracique
37. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
38. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
39. Are liquid biopsies a surrogate for tissue EGFR testing?
40. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
41. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups
42. CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies
43. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
44. Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
45. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
46. Les tumeurs thymiques
47. Prise en charge des métastases cérébrales des carcinomes bronchiques
48. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience
49. Thymic malignancies: Moving forward with new systemic treatments
50. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.